Biolegend, 329930, Brilliant Violet 785™ anti-human CD279 (PD-1) Antibody, 100tests

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.
100tests
Verified Reactivity: Human
Reported Reactivity: African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA) Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA) Velu V, et al. 2007. J. Virol. 81:5819. (FA) Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA) Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity) Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC) Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG) Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Preglej T, et al. 2023. Front Immunol. 14:1096096. PubMed Doloff JC, et al. 2023. Sci Adv. 9:eade9488. PubMed Lorvik KB, et al. 2021. Front Immunol. 12:744155. PubMed Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed McEvoy CM, et al. 2022. Nat Commun. 13:7634. PubMed Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed Hoang TN, et al. 2021. Cell. 184:460. PubMed Barry KC, et al. 2018. Nat Med. 24:1178. PubMed Pauthner MG, et al. 2019. Immunity. 50:241. PubMed Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed Di Blasi D, et al. 2019. Cell Mol Gastroenterol Hepatol. 0.510416667. PubMed Silva M, et al. 2021. Sci Immunol. 6:eabf1152. PubMed Tardif V, et al. 2019. Nat Commun. 10:823. PubMed Hoang TN, et al. 2020. bioRxiv. . PubMed Herati R, et al. 2014. J Immunol. 193:3528. PubMed Yu C, et al. 2021. Med (N Y). 2:755. PubMed Nishimura Y, et al. 2017. Nature. 543:559. PubMed Vardam-Kaur T, et al. 2021. Oncotarget. 12:2051. PubMed Harper JL, et al. 2020. Nat Med. 519:26. PubMed Colomb F, et al. 2020. Cell Reports. 32(5):107991. PubMed Gyurdieva A, et al. 2022. Nat Commun. 13:5296. PubMed Del Alcazar D, et al. 2019. Cell Rep. 28:3047. PubMed Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed Rydyznski Moderbacher C, et al. 2020. Cell. 183(4):996-1012.e19. PubMed Dan J, et al. 2016. J Immunol. 197: 983 - 993. PubMed Cirelli KM et al. 2019. Cell. 177(5):1153-1171 . PubMed Zhang P, et al. 2021. Nat Med. 22:. PubMed Ireland RE, et al. 2022. Viruses. 14:. PubMed Rydyznski Moderbacher C, et al. 2022. J Clin Invest. :. PubMed Panigrahi S, et al. 2020. Eur J Immunol. 50:2055. PubMed Schreurs RRCE, et al. 2019. Immunity. 50:462. PubMed
RRID: AB_11218984 (BioLegend Cat. No. 329929) AB_2563443 (BioLegend Cat. No. 329930)
Structure: Immunoglobulin superfamily
Distribution: Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells
Ligand/Receptor: B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type: B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Gene ID: 5133
UniProt: View information about CD279 on UniProt.org
Clone: EH12.2H7
Regulatory Status: RUO
Other Names: PD-1, PDCD1
Isotype: Mouse IgG1, κ